Collectively, our data provide a strong rationale for clinical testing of dual targeting of FGFR and CCND1/CDK4 in NSCLC patients with FGF3/4/19/CCND1-amplification tumor resistant to gefitinib. The gene discussed is FGF3; the disease is neoplasm.